Cantor Fitzgerald Brokers Raise Earnings Estimates for Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) – Stock analysts at Cantor Fitzgerald increased their FY2024 earnings per share estimates for shares of Regeneron Pharmaceuticals in a research note issued on Monday, April 22nd. Cantor Fitzgerald analyst O. Brayer now forecasts that the biopharmaceutical company will earn $37.72 per share for the year, up from their previous estimate of $37.66. Cantor Fitzgerald has a “Neutral” rating and a $925.00 price target on the stock. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $38.80 per share.

Several other equities analysts have also recently issued reports on the company. Bank of America upped their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research report on Friday, April 12th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. Truist Financial reissued a “buy” rating and set a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a report on Wednesday, April 3rd. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target on the stock. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $1,189.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $976.41.

Regeneron Pharmaceuticals Stock Performance

REGN stock opened at $907.32 on Tuesday. The stock has a market capitalization of $99.59 billion, a PE ratio of 26.11, a price-to-earnings-growth ratio of 2.58 and a beta of 0.11. Regeneron Pharmaceuticals has a 12-month low of $684.80 and a 12-month high of $998.33. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The stock’s 50 day simple moving average is $951.41 and its 200 day simple moving average is $893.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.73 by $1.13. The business had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm’s quarterly revenue was up .6% on a year-over-year basis. During the same period in the prior year, the firm posted $10.96 EPS.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of REGN. Norges Bank bought a new position in Regeneron Pharmaceuticals in the fourth quarter worth approximately $932,571,000. FMR LLC raised its stake in Regeneron Pharmaceuticals by 7.3% in the third quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after buying an additional 669,517 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Regeneron Pharmaceuticals by 76,169.5% during the fourth quarter. International Assets Investment Management LLC now owns 591,089 shares of the biopharmaceutical company’s stock worth $519,148,000 after purchasing an additional 590,314 shares in the last quarter. Global Assets Advisory LLC acquired a new position in shares of Regeneron Pharmaceuticals during the first quarter worth $339,594,000. Finally, First Trust Advisors LP increased its position in shares of Regeneron Pharmaceuticals by 115.2% during the fourth quarter. First Trust Advisors LP now owns 365,950 shares of the biopharmaceutical company’s stock worth $321,410,000 after purchasing an additional 195,902 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Insider Buying and Selling

In related news, EVP Andrew J. Murphy sold 5,783 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The stock was sold at an average price of $956.47, for a total transaction of $5,531,266.01. Following the completion of the transaction, the executive vice president now owns 48,306 shares in the company, valued at $46,203,239.82. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at approximately $12,888,716.19. The disclosure for this sale can be found here. Over the last quarter, insiders sold 11,022 shares of company stock worth $10,552,991. Corporate insiders own 8.83% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.